Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

2.

The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P, Vermeulen J, Vandesompele J, Speleman F.

Genome Med. 2009 Jul 27;1(7):74. doi: 10.1186/gm74.

3.

CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23.

Michels E, Hoebeeck J, De Preter K, Schramm A, Brichard B, De Paepe A, Eggert A, Laureys G, Vandesompele J, Speleman F.

BMC Cancer. 2008 Jun 17;8:173. doi: 10.1186/1471-2407-8-173.

4.

methBLAST and methPrimerDB: web-tools for PCR based methylation analysis.

Pattyn F, Hoebeeck J, Robbrecht P, Michels E, De Paepe A, Bottu G, Coornaert D, Herzog R, Speleman F, Vandesompele J.

BMC Bioinformatics. 2006 Nov 9;7:496.

5.

No evidence for involvement of SDHD in neuroblastoma pathogenesis.

De Preter K, Vandesompele J, Hoebeeck J, Vandenbroecke C, Smet J, Nuyts A, Laureys G, Combaret V, Van Roy N, Roels F, Van Coster R, Praet M, De Paepe A, Speleman F.

BMC Cancer. 2004 Aug 24;4:55.

Supplemental Content

Loading ...
Support Center